![](/cdn/assets/images/search/clock.png)
We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
---|---|---|---|---|---|
Medgenics(Regs) | LSE:MEDG | London | Ordinary Share | COM SHS USD0.0001 (REGS) |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
0.00 | 0.00% | 302.50 | 0.00 | 01:00:00 |
Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
---|---|---|---|---|---|
0 | 0 | N/A | 0 |
TIDMMEDG TIDMMEDU
RNS Number : 3462P
Medgenics Inc
30 September 2011
Medgenics, Inc.
(the "Company")
Directors' dealings and issue of equity
30 September 2011
Medgenics, Inc. (NYSE Amex: MDGN and London Stock Exchange - AIM: MEDG and MEDU), the developer of a novel technology for the sustained production and delivery of therapeutic proteins in patients using their own tissue, reports that it was notified on 7 September 2011 that on that date Gary Brukardt, a director of the Company, exercised warrants to subscribe for 45,701 common shares of par value U.S. $0.0001 in the Company ("Common Shares"), at an exercise price of $2.49 each, using the cashless exercise mechanism resulting in the issue to him of 16,197 Common Shares. These Common Shares were issued on 28 September 2011.
Additionally, the Company was notified on 22 September 2011 that, on that date, Andrew Pearlman, President, CEO and a director of the Company, transferred warrants to subscribe for 200,000 Common Shares at an exercise price of $2.49 per Common Share ("Warrants") at nil consideration in equal tranches of 50,000 Warrants to each of the following trusts (Andrew Pearlman and Debbie Pearlman are the sole trustees for each trust):
1. Pearlman Family Trust for the benefit of Micah Chaim Pearlman
2. Pearlman Family Trust for the benefit of Adina Rachel Pearlman
3. Pearlman Family Trust for the benefit of Cela Shoshana Pearlman
4. Pearlman Friends and Family Trust
On 26 September 2011, the Company also issued 12,500 Common Shares at $3.76 (calculated with reference to the mid market price of the Common Shares at the close of the previous business day) in consideration for consulting services. It is expected that these Common Shares together with those issued to Gary Brukardt will be admitted to trading on AIM on 7 October 2011.
As of 30 September 2011 and following the above exercise and share issuance (and a further 30,222 Common Shares issued as a result of the exercise of options and warrants which will be admitted under the block listing application of 6 July 2011), the Company has 9,690,117 Common Shares in issue and has approximately 33 per cent. of Common Shares not in public hands and the amended holdings of Gary Brukardt and Andrew Pearlman (including their related parties as defined by the AIM Rules) are as follows:
% of % of Issued Issued Common Share Expiry Exercise Total Share Name Shares Capital Instrument Number Date Price interests Capital Andrew L. Pearlman (Director) & related Warrants interests(*) 35,375 ** 905,190 31/03/2016 $2.49 Warrants 35,922 31/03/2016 $0.0002 Options 182,806 31/03/2016 $2.49 Options 91,403 14/11/2012 $7.35 ------- -------- ----------- ---------- ----------- --------- ---------- -------- Total 35,375 0.4% 1,215,321 1,250,696 12.9% Gary Brukardt (Director) 66,077 Options 26,705 14/11/2012 $7.35 Options 28,571 13/09/2020 $8.19 Options 12,857 05/01/2021 $6.55 ------- -------- ----------- ---------- ----------- --------- ---------- -------- Total 66,077 0.7% 68,133 134,219 1.4%
Notes
(*) Including interests in 94 Common Shares held by family members and 1,719 Common Shares held by ADP Holdings LLC, a company in which Dr. Pearlman is interested
(**) Including warrants over 50,000 Common Shares with an expiry date of 31/03/2016 and an exercise price of $2.49 in each of the Pearlman Family Trust for the benefit of Micah Chaim Pearlman, the Pearlman Family Trust for the benefit of Adina Rachel Pearlman, the Pearlman Family Trust for the benefit of Cela Shoshana Pearlman and the Pearlman Friends and Family Trust.
For further information, contact:
Medgenics, Inc. Phone: +972 4 902 8900 Dr. Andrew L. Pearlman ------------------------------------- ------------------------ Religare Capital Markets (Nominated Phone: +44 20 7444 0800 Adviser) James Pinner Derek Crowhurst ------------------------------------- ------------------------ SVS Securities plc (Joint Broker) Phone: +44 20 7638 5600 Ian Callaway ------------------------------------- ------------------------ Nomura Code Securities PLC (Joint Phone: +44 20 7776 1219 Broker) Jon Senior ------------------------------------- ------------------------ De Facto Communications Phone: +44 20 7861 3838 Mike Wort Anna Dunphy ------------------------------------- ------------------------ Lippert/Heilshorn & Associates, Inc. Phone: +1 212 838 3777 (Investment Relations - US) Anne Marie Fields ------------------------------------- ------------------------
<ENDS>
This information is provided by RNS
The company news service from the London Stock Exchange
END
RDSEALNEDSDFEFF
1 Year Medgenics(Regs) Chart |
1 Month Medgenics(Regs) Chart |
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions